That's quite interesting. I used to work in a lab that researched Wilson disease (the copper toxicity disorder the drug treats). Actually, increased copper levels in the brain have been linked to a myriad of other conditions, such as Alzheimers.
Anyway, thinking as a big pharma might, one might suspect that they may not be as interested in investing too heavily in clinical trials for a drug that has been around since the mid 80s but I think that there is some promise in TETA.
KZA is well ahead of the game in many regards and it will be interesting to see the data that is coming, hopefully soon?
KZA Price at posting:
82.5¢ Sentiment: Buy Disclosure: Held
